Cover Image
Market Research Report

Europe Hemostats and Tissue Sealants Market Forecast 2019-2027

Published by Inkwood Research Product code 754272
Published Content info 90 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Hemostats and Tissue Sealants Market Forecast 2019-2027
Published: February 16, 2019 Content info: 90 Pages
Description

KEY FINDINGS

The United Kingdom, Germany, France, Italy, Spain & Rest of Europe are the countries considered for this market analysis. The hemostats and tissue sealants market was valued at $ xx million in 2018 and is expected to reach $ xx million by 2027. This particular regional market is growing at CAGR of 7.46% from 2019 to 2027.

MARKET INSIGHTS

The United Kingdom has the second largest market for hemostasis and sealing agents in Europe, but is the fastest growing market because of a few promotional incentives by governmental institutions. For example, the National Health Service (NHS) is offering low-cost to free-of-cost treatments to unemployed or retired patients who undergo treatments in NHS run hospitals. Also, a well-integrated healthcare network in the country helps drive market growth significantly.

COMPETITIVE INSIGHTS

Smith & Nephew PLC, Integra Lifesciences Corp., Advanced Medical Solutions (AMS) Group PLC, Baxter International Inc., B.Braun Melsungen AG, Cohera Medical Inc., Cryolife Inc., CSL Behring, Hyperbranch Medical Technology, Inc. (Acquired by Stryker), Johnson & Johnson, Medtronic PLC, Pfizer, Inc. and C.R. Bard, Inc. are the chief competing market players in the Europe hemostats and tissue sealants market.

Table of Contents
Product Code: 22706

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. TOPICAL HEMOSTAT HOLDS THE LARGEST MARKET SHARE AND IS ANTICIPATED TO GROW AT A FASTER RATE DURING THE FORECAST PERIOD
    • 3.2.2. SYNTHETIC TISSUE SEALANTS OF THE ADHESIVE AND TISSUE SEALANTS HOLDS THE LARGEST MARKET SHARE

4. MARKET DYNAMICS

  • 4.1. MARKET SCOPE & DEFINITION
  • 4.2. MARKET DRIVERS
    • 4.2.1. INCREASING INCIDENCE OF CHRONIC DISEASES
    • 4.2.2. INCREASE IN AGING POPULATION
    • 4.2.3. INCREASE IN NUMBER OF SURGERIES
  • 4.3. MARKET RESTRAINTS
    • 4.3.1. STRINGENT REGULATIONS
    • 4.3.2. ADVERSE REACTIONS AND COMPLICATIONS
  • 4.4. MARKET OPPORTUNITIES
    • 4.4.1. USAGE OF HEMOSTASIS DEVICES AND TISSUE SEALANTS IN MULTIPLE CONDITIONS
    • 4.4.2. ACCESSIBILITY OF MORE TREATMENT OPTIONS FOR MEDICAL PROFESSIONALS
  • 4.5. MARKET CHALLENGES
    • 4.5.1. LIMITATIONS ASSOCIATED WITH HEMOSTATS AND TISSUE SEALANTS
    • 4.5.2. PRODUCT SIDE EFFECTS AND FDA SCRUTINY

5. MARKET BY PRODUCTS

  • 5.1. TOPICAL HEMOSTAT
    • 5.1.1. MECHANICAL HEMOSTATS
    • 5.1.2. ACTIVE HEMOSTATS
    • 5.1.3. FLOWABLE HEMOSTATS
  • 5.2. ADHESIVE AND TISSUE SEALANTS
    • 5.2.1. SYNTHETIC TISSUE SEALANT
      • 5.2.1.1. OXIDIZED REGENERATED CELLULOSE
      • 5.2.1.2. CYANOACRYLATE ADHESIVES
      • 5.2.1.3. OTHER SYNTHETIC TISSUE SEALANTS
    • 5.2.2. NATURAL TISSUE SEALANT
      • 5.2.2.1. CHITIN AND CHITOSAN BASED HEMOSTATIC AGENT
      • 5.2.2.2. OTHER NATURAL TISSUE SEALANT
    • 5.2.3. ADHESION BARRIER PRODUCTS

6. KEY ANALYTICS

  • 6.1. PORTER'S FIVE FORCE MODEL
    • 6.1.1. THREAT OF NEW ENTRANTS
    • 6.1.2. THREAT OF SUBSTITUTE
    • 6.1.3. BARGAINING POWER OF SUPPLIERS
    • 6.1.4. BARGAINING POWER OF BUYERS
    • 6.1.5. THREAT OF COMPETITIVE RIVALRY
  • 6.2. POLITICAL & LEGAL, ECONOMIC AND TECHNOLOGICAL SWOT ANALYSIS OF HEMOSTATS AND TISSUE SEALANTS MARKET
    • 6.2.1. POLITICAL & LEGAL
    • 6.2.2. ECONOMIC
    • 6.2.3. TECHNOLOGICAL
  • 6.3. MARKET TRENDS
  • 6.4. OPPORTUNITY MATRIX

7. GEOGRAPHICAL ANALYSIS

  • 7.1. EUROPE
    • 7.1.1. THE UNITED KINGDOM
    • 7.1.2. GERMANY
    • 7.1.3. FRANCE
    • 7.1.4. ITALY
    • 7.1.5. SPAIN
    • 7.1.6. REST OF EUROPE

8. COMPETITIVE LANDSCAPE

  • 8.1. MARKET POSITION ANALYSIS
  • 8.2. COMPANY PROFILES
    • 8.2.1. ADVANCED MEDICAL SOLUTIONS (AMS) GROUP PLC
      • 8.2.1.1. COMPANY OVERVIEW
      • 8.2.1.2. PRODUCT PORTFOLIO
      • 8.2.1.3. STRATEGIC INITIATIVES
    • 8.2.2. BAXTER INTERNATIONAL INC.
      • 8.2.2.1. COMPANY OVERVIEW
      • 8.2.2.2. PRODUCT PORTFOLIO
      • 8.2.2.3. SCOT ANALYSIS
      • 8.2.2.4. STRATEGIC INITIATIVES
    • 8.2.3. B.BRAUN MELSUNGEN AG
      • 8.2.3.1. OVERVIEW
      • 8.2.3.2. PRODUCT PORTFOLIO
      • 8.2.3.3. SCOT ANALYSIS
      • 8.2.3.4. STRATEGIC ANALYSIS
    • 8.2.4. COHERA MEDICAL INC.
      • 8.2.4.1. COMPANY OVERVIEW
      • 8.2.4.2. PRODUCT PORTFOLIO
      • 8.2.4.3. STRATEGIC INITIATIVES
    • 8.2.5. C. R. BARD, INC.
      • 8.2.5.1. COMPANY OVERVIEW
      • 8.2.5.2. PRODUCT PORTFOLIO
      • 8.2.5.3. SCOT ANALYSIS
      • 8.2.5.4. STRATEGIC INITIATIVES
    • 8.2.6. CRYOLIFE INC.
      • 8.2.6.1. COMPANY OVERVIEW
      • 8.2.6.2. PRODUCT PORTFOLIO
      • 8.2.6.3. STRATEGIC INITIATIVES
    • 8.2.7. CSL BEHRING
      • 8.2.7.1. COMPANY OVERVIEW
      • 8.2.7.2. PRODUCT PORTFOLIO
      • 8.2.7.3. STRATEGIC INITIATIVES
    • 8.2.8. HYPERBRANCH MEDICAL TECHNOLOGY, INC. (ACQUIRED BY STRYKER)
      • 8.2.8.1. COMPANY OVERVIEW
      • 8.2.8.2. PRODUCT PORTFOLIO
      • 8.2.8.3. STRATEGIC INITIATIVES
    • 8.2.9. INTEGRA LIFESCIENCES CORP
      • 8.2.9.1. COMPANY OVERVIEW
      • 8.2.9.2. PRODUCT PORTFOLIO
      • 8.2.9.3. SCOT ANALYSIS
      • 8.2.9.4. STRATEGIC INITIATIVES
    • 8.2.10. JOHNSON AND JOHNSON
      • 8.2.10.1. COMPANY OVERVIEW
      • 8.2.10.2. PRODUCT PORTFOLIO
      • 8.2.10.3. SCOT ANALYSIS
      • 8.2.10.4. STRATEGIC INITIATIVES
    • 8.2.11. MEDTRONIC PLC
      • 8.2.11.1. COMPANY OVERVIEW
      • 8.2.11.2. PRODUCT PORTFOLIO
      • 8.2.11.3. SCOT ANALYSIS
      • 8.2.11.4. STRATEGIC INITIATIVES
    • 8.2.12. PFIZER, INC.
      • 8.2.12.1. COMPANY PROFILES
      • 8.2.12.2. PRODUCT PORTFOLIO
      • 8.2.12.3. SCOT ANALYSIS
      • 8.2.12.4. STRATEGIC INITIATIVES
    • 8.2.13. SMITH AND NEPHEW PLC
      • 8.2.13.1. MARKET OVERVIEW
      • 8.2.13.2. PRODUCT PORTFOLIO
      • 8.2.13.3. SCOT ANALYSIS
      • 8.2.13.4. STRATEGIC INITIATIVE
    • 8.2.14. ZIMMER BIOMET HOLDINGS INC
      • 8.2.14.1. MARKET OVERVIEW
      • 8.2.14.2. PRODUCT PORTFOLIO
      • 8.2.14.3. SCOT ANALYSIS
      • 8.2.14.4. STRATEGIC INITIATIVES

LIST OF TABLES

  • TABLE 1 EUROPE HEMOSTATS AND TISSUE SEALANTS MARKET 2019-2027 ($ MILLION)
  • TABLE 2 EUROPE HEMOSTATS AND TISSUE SEALANTS MARKET BY PRODUCTS 2019-2027 ($ MILLION)
  • TABLE 3 EUROPE TOPICAL HEMOSTAT MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 4 EUROPE TOPICAL HEMOSTAT MARKET 2019-2027 ($ MILLION)
  • TABLE 5 EUROPE MECHANICAL HEMOSTATS MARKET 2019-2027 ($ MILLION)
  • TABLE 6 EUROPE ACTIVE HEMOSTATS MARKET 2019-2027 ($ MILLION)
  • TABLE 7 EUROPE FLOWABLE HEMOSTATS MARKET 2019-2027 ($ MILLION)
  • TABLE 8 EUROPE ADHESIVE AND TISSUE SEALANTS MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 9 EUROPE ADHESIVE AND TISSUE SEALANTS MARKET 2019-2027 ($ MILLION)
  • TABLE 10 EUROPE SYNTHETIC TISSUE SEALANT MARKET 2019-2027 ($ MILLION)
  • TABLE 11 EUROPE SYNTHETIC TISSUE SEALANT MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 12 EUROPE OXIDIZED REGENERATED CELLULOSE MARKET 2019-2027 ($ MILLION)
  • TABLE 13 EUROPE CYANOACRYLATE ADHESIVES MARKET 2019-2027 ($ MILLION)
  • TABLE 14 EUROPE OTHER SYNTHETIC TISSUE SEALANTS MARKET 2019-2027 ($ MILLION)
  • TABLE 15 EUROPE NATURAL TISSUE SEALANT MARKET 2019-2027 ($ MILLION)
  • TABLE 16 EUROPE NATURAL TISSUE SEALANT MARKET BY TYPES 2019-2027 ($ MILLION)
  • TABLE 17 EUROPE CHITIN AND CHITOSAN BASED HEMOSTATIC AGENT MARKET 2019-2027 ($ MILLION)
  • TABLE 18 EUROPE OTHER NATURAL TISSUE SEALANT MARKET 2019-2027 ($ MILLION)
  • TABLE 19 EUROPE ADHESION BARRIER PRODUCTS MARKET BY REAGENTS 2019-2027 ($ MILLION)
  • TABLE 20 EUROPE HEMOSTATS AND TISSUE SEALANTS MARKET BY COUNTRY 2019-2027 ($ MILLION)
  • TABLE 21 HEMOSTATS COMPANY MARKET POSITION ANALYSIS 2017 (%)
  • TABLE 22 TISSUE SEALANTS COMPANY MARKET POSITION ANALYSIS 2017 (%)

LIST OF FIGURES

  • FIGURE 1 PROCESS OF COAGULATION
  • FIGURE 2 EUROPE HEMOSTATS AND TISSUE SEALANTS MARKET 2018-2026 ($ MILLION)
  • FIGURE 3 EUROPE HEMOSTATS AND TISSUE SEALANTS MARKET SHARE BY PRODUCTS 2018 & 2027 (%)
  • FIGURE 4 EUROPE HEMOSTATS AND TISSUE SEALANTS MARKET BY TOPICAL HEMOSTAT 2019-2027 ($ MILLION)
  • FIGURE 5 EUROPE TOPICAL HEMOSTAT MARKET BY MECHANICAL HEMOSTATS 2019-2027 ($ MILLION)
  • FIGURE 6 EUROPE TOPICAL HEMOSTAT MARKET BY ACTIVE HEMOSTATS 2019-2027 ($ MILLION)
  • FIGURE 7 EUROPE TOPICAL HEMOSTAT MARKET BY FLOWABLE HEMOSTATS 2019-2027 ($ MILLION)
  • FIGURE 8 EUROPE HEMOSTATS AND TISSUE SEALANTS MARKET BY ADHESIVE AND TISSUE SEALANTS 2019-2027 ($ MILLION)
  • FIGURE 9 EUROPE ADHESIVE AND TISSUE SEALANTS MARKET BY SYNTHETIC TISSUE SEALANT 2019-2027 ($ MILLION)
  • FIGURE 10 EUROPE SYNTHETIC TISSUE SEALANT MARKET BY OXIDIZED REGENERATED CELLULOSE 2019-2027 ($ MILLION)
  • FIGURE 11 EUROPE SYNTHETIC TISSUE SEALANT MARKET BY CYANOACRYLATE ADHESIVES 2019-2027 ($ MILLION)
  • FIGURE 12 EUROPE SYNTHETIC TISSUE SEALANT MARKET BY OTHER SYNTHETIC TISSUE SEALANTS 2019-2027 ($ MILLION)
  • FIGURE 13 EUROPE ADHESIVE AND TISSUE SEALANTS MARKET BY NATURAL TISSUE SEALANT 2019-2027 ($ MILLION)
  • FIGURE 14 EUROPE NATURAL TISSUE SEALANT MARKET BY CHITIN AND CHITOSAN BASED HEMOSTATIC AGENT 2019-2027 ($ MILLION)
  • FIGURE 15 EUROPE NATURAL TISSUE SEALANT MARKET BY CHITIN AND OTHER NATURAL TISSUE SEALANT 2019-2027 ($ MILLION)
  • FIGURE 16 EUROPE ADHESIVE AND TISSUE SEALANTS MARKET BY ADHESION BARRIER PRODUCTS 2019-2027 ($ MILLION)
  • FIGURE 17 PORTER'S FIVE FORCE MODEL
  • FIGURE 18 EUROPE HEMOSTATS AND TISSUE SEALANTS MARKET REGIONAL OUTLOOK 2018 & 2027 (%)
  • FIGURE 19 THE UNITED KINGDOM HEMOSTATS AND TISSUE SEALANTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 20 GERMANY HEMOSTATS AND TISSUE SEALANTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 21 FRANCE HEMOSTATS AND TISSUE SEALANTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 22 ITALY HEMOSTATS AND TISSUE SEALANTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 23 SPAIN HEMOSTATS AND TISSUE SEALANTS MARKET 2019-2027 ($ MILLION)
  • FIGURE 24 REST OF EUROPE HEMOSTATS AND TISSUE SEALANTS MARKET 2019-2027 ($ MILLION)
Back to Top